Technologies for preserving kidney function in patients with chronic kidney disease and hyperuricemia
Keywords:chronic kidney disease, hyperuricemia, renal replacement therapy
The prevalence of chronic kidney disease (CKD) and hyperuricemia is increasing globally. The steady increase in the number of patients with impaired renal function associated with diabetes mellitus, arterial hypertension, and an increase in life expectancy ultimately leads to significant costs associated with the need to use expensive methods of renal replacement therapy. The main task for physicians is the timely determination and slowing down of the progression of CKD, and renoprotection. Hyperuricemia is considered an independent risk factor for the onset and progression of the disease, in addition to the traditional microalbuminuria and decreased glomerular filtration rate. The urgency of detecting hyperuricemia is due to the possibility of its further correction to improve the prognosis of the disease and delay the end stage of CKD, improve the quality of life and reduce the cost of treatment of patients. A decrease in the total pool of uric acid in the body helps to minimize the risk of arthropathy and nephrolithiasis, exacerbation of gout, progression of renal failure and other complications. However, despite hundreds of published clinical studies on the diagnosis and treatment of patients with CKD, the quality of care remains suboptimal. The article presents versatile technologies of preserving renal function in patients with CKD and hyperuricemia, which require improvement.
Oh TR, Choi HS, Kim CS, et al. Hyperuricemia has increased the risk of progression of chronic kidney disease: propensity score matching analysis from the KNOW-CKD study. Sci Rep. 2019 Apr 30;9(1):6681. doi:10.1038/s41598-019-43241-3.
Kim CS, Jin DC, Yun YC, Bae EH, Ma SK, Kim SW. Relationship between serum uric acid and mortality among hemodialysis patients: Retrospective analysis of Korean end-stage renal disease registry data. Kidney Res Clin Pract. 2017 Dec;36(4):368-376. doi:10.23876/j.krcp.2017.36.4.368.
Chini LSN, Assis LIS, Lugon JR. Relationship between uric acid levels and risk of chronic kidney disease in a retrospective cohort of Brazilian workers. Braz J Med Biol Res. 2017 Aug 7;50(9):e6048. doi:10.1590/1414-431X20176048.
Mount DB. Hypouricemia: сauses and clinical significance. Available from: https://www.uptodate.com/contents/hypouricemia-causes-and-clinical-significance. Accessed: September 14, 2020.
GBD 2015 Mortality and Causes of Death Collaborators. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016 Oct 8;388(10053):1459-1544. doi:10.1016/S0140-6736(16)31012-1.
Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int. 2011 Dec;80(12):1258-1270. doi:10.1038/ki.2011.368.
Levin A, Stevens PE, Bilous RW, et al. Kidney Disease Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3(1):1-150. doi:10.1038/kisup.2012.73.
National Collaborating Centre for Chronic Conditions (UK). Chronic Kidney Disease: National Clinical Guideline for Early Identification and Management in Adults in Primary and Secondary Care. London: Royal College of Physicians (UK); 2008. 237 p.
Chevalier RL. The proximal tubule is the primary target of injury and progression of kidney disease: role of the glomerulotubular junction. Am J Physiol Renal Physiol. 2016 Jul 1;311(1):F145-161. doi:10.1152/ajprenal.00164.2016.
Sarvepalli PS, Fatima M, Quadri AK, et al. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1050-1056. doi:10.4103/1319-2442.243953.
Roughley M, Sultan AA, Clarson L, et al. Risk of chronic kidney disease in patients with gout and the impact of urate lowering therapy: a population-based cohort study. Arthritis Res Ther. 2018 Oct 30;20(1):243. doi:10.1186/s13075-018-1746-1.
Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006 Jan;47(1):51-59. doi:10.1053/j.ajkd.2005.10.006.
Liu P, Chen Y, Wang B, Zhang F, Wang D, Wang Y. Allopurinol treatment improves renal function in patients with type 2 diabetes and asymptomatic hyperuricemia: 3-year randomized parallel-controlled study. Clin Endocrinol (Oxf). 2015 Oct;83(4):475-482. doi:10.1111/cen.12673.
Helal I, McFann K, Reed B, Yan XD, Schrier RW, Fick-Brosnahan GM. Serum uric acid, kidney volume and progression in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant. 2013 Feb;28(2):380-385. doi:10.1093/ndt/gfs417.
Hart A, Jackson S, Kasiske BL, et al. Uric acid and allograft loss from interstitial fibrosis/tubular atrophy: post hoc analysis from the angiotensin II blockade in chronic allograft nephropathy trial. Transplantation. 2014 May 27;97(10):1066-1071. doi:10.1097/01.TP.0000440952.29757.66.
Li Q, Li X, Wang J, et al. Diagnosis and treatment for hyperuricemia and gout: a systematic review of clinical practice guidelines and consensus statements. BMJ Open. 2019 Aug 24;9(8):e026677. doi:10.1136/bmjopen-2018-026677.
Savyc'ka LM. Rol' stanu funkcional'nogo nyrkovogo rezervu, rivniv sechovoi' kysloty ta magniju u progresuvanni hronichnoi' hvoroby nyrok: diss. kand. med. nauk. med. nauk [The role of functional renal reserve, uric acid and magnesium levels in the progression of chronic kidney disease. PhD in med sci diss.]. Zaporizhzhia; 2020. 21 p. (in Ukrainian).
Pascart T, Latourte A, Flipo RM, et al. 2020 recommendations from the French Society of Rheumatology for the management of gout: Urate-lowering therapy. Joint Bone Spine. 2020 Oct;87(5):395-404. doi:10.1016/j.jbspin.2020.05.002.
Hisatome I, Li P, Miake J, et al. Uric Acid as a Risk Factor for Chronic Kidney Disease and Cardiovascular Disease - Japanese Guideline on the Management of Asymptomatic Hyperuricemia. Circ J. 2021 Jan 25;85(2):130-138. doi:10.1253/circj.CJ-20-0406.
Qaseem A, McLean RM, Starkey M, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Diagnosis of Acute Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):52-57. doi:10.7326/M16-0569.
Qaseem A, Harris RP, Forciea MA; Clinical Guidelines Committee of the American College of Physicians. Management of Acute and Recurrent Gout: A Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2017 Jan 3;166(1):58-68. doi:10.7326/M16-0570.
Roddy E, Packham J, Obrenovic K, Rivett A, Ledingham JM. Management of gout by UK rheumatologists: a British Society for Rheumatology national audit. Rheumatology (Oxford). 2018 May 1;57(5):826-830. doi:10.1093/rheumatology/kex521.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our edition uses the copyright terms of Creative Commons for open access journals.
Authors, who are published in this journal, agree with the following terms:
- The authors retain rights for authorship of their article and grant to the edition the right of first publication of the article on a Creative Commons Attribution 4.0 International License, which allows others to freely distribute the published article, with the obligatory reference to the authors of original works and original publication in this journal.
- Directing the article for the publication to the editorial board (publisher), the author agrees with transmitting of rights for the protection and using the article, including parts of the article, which are protected by the copyrights, such as the author’s photo, pictures, charts, tables, etc., including the reproduction in the media and the Internet; for distributing; for the translation of the manuscript in all languages; for export and import of the publications copies of the writers’ article to spread, bringing to the general information.
- The rights mentioned above authors transfer to the edition (publisher) for the unlimited period of validity and on the territory of all countries of the world.
- The authors guarantee that they have exclusive rights for using of the article, which they have sent to the edition (publisher). The edition (the publisher) is not responsible for the violation of given guarantees by the authors to the third parties.
- The authors have the right to conclude separate supplement agreements that relate to non-exclusive distribution of their article in the form in which it had been published in the journal (for example, to upload the work to the online storage of the journal or publish it as part of a monograph), provided that the reference to the first publication of the work in this journal is included.
- The policy of the journal permits and encourages the publication of the article in the Internet (in institutional repository or on a personal website) by the authors, because it contributes to productive scientific discussion and a positive effect on efficiency and dynamics of the citation of the article.
- The rights to the article are deemed transferred by the authors to the edition (the publisher) since the moment of the publication of the article in the printed or electronic version of journal.